Benjamin Lemasson1,2, Raphal Serduc3,
Cecile Maisin1,4, Audrey Bouchet3, Nicolas Coquery1,4,
Philippe Robert5, Christopoh Segebarth1,4, Graldine Le
Duc3, Irne Tropres1,4, Chantal Rmy1,4,
Emmanuel Louis Barbier1,4
1Inersm U836, Grenoble, France; 2Oncodesign
Biotechnology, Dijon, France; 3ESRF, Grenoble, France; 4Universit
Joseph Fourier, Grenoble Institut des Neurosciences, Grenoble, France; 5Guerbet
Research, Aulnay-Sous-Bois, France
Numerous
anti-tumor therapies modify the permeability (increase or decrease) of
tumoral or healthy vessels. Permeability can be assessed by Dynamic
Contrast-Enhanced-MRI (DCE-MRI). Low- (0.5kDa) and macro (3.5kDa)
-molecular-weight-CM, DCE-MRI was performed within the same imaging session
on 80 rats bearing 9L gliosarcoma before and three times after treatments
onset (antiangiogenic and/or synchrotron radiotherapy), searching for
possible increase or decrease in vessel wall permeability. This study
suggests that the choice of CM for a DCE-MRI depends on the physiological
questions to be addressed. It also suggests that the use of two CM within the
same MRI session is feasible.